BioAtla BCAB
NASDAQ BCAB
$1.40 +0.08 (+6.06%)
At close: Sep 8, 2026 · 4:00 PM EDT

BioAtla (BCAB) Non-Current Assets (2020 - 2026)

BioAtla's (BCAB) quarterly Non-Current Assets came in at $5.2 million in Q2 2026, down 19.46% on a YoY basis from $6.5 million in Q2 2025, and down 4.11% quarter-over-quarter from $5.5 million in Q1 2026.

Analysis

BioAtla (BCAB) Non-Current Assets (2020 - 2026) Analysis & Trends

BioAtla (BCAB) has reported Non-Current Assets for 7 consecutive years, with $5.2 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Non-Current Assets fell 19.46% year-over-year to $5.2 million; the trailing twelve-month figure through Jun 2026 stood at $22.8 million (up 124.86% YoY), and the FY2025 full-year result was $5.8 million, up 388.66% from the prior year.
  • Non-Current Assets eased to $5.2 million in Q2 2026 per BCAB's latest filing, from $5.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $6.6 million in Q1 2022 and bottomed at $753000.0 in Q1 2025.
  • Historically, Non-Current Assets has averaged $4.3 million across 5 years, with a median of $5.0 million in 2023.
  • The sharpest annual moves came in 2025 and 2026: Non-Current Assets sank 72.84% in 2025, then surged 626.83% in 2026.
  • Over 5 years, Non-Current Assets stood at $5.3 million in 2022, then slumped by 38.7% to $3.3 million in 2023, then tumbled by 63.41% to $1.2 million in 2024, then soared by 388.66% to $5.8 million in 2025, then retreated by 9.75% to $5.2 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods registered $5.2 million, $5.5 million, and $5.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Assets (Qtr)
1 Amgen 206.24 Bn 192.25 Bn 7.24 Bn 60.68 Bn
2 Gilead Sciences 180.01 Bn 176.83 Bn 6.22 Bn 35.42 Bn
3 Vertex Pharmaceuticals 131.33 Bn 123.47 Bn 2.84 Bn 14.88 Bn
4 Regeneron Pharmaceuticals 81.87 Bn 73.87 Bn 3.93 Bn 23.28 Bn
5 Argenx Se 60.27 Bn 55.08 Bn 1.37 Bn 1.96 Bn
6 Moderna 53.93 Bn 48.79 Bn 52.00 Mn 5.15 Bn
7 Alnylam Pharmaceuticals 33.17 Bn 29.86 Bn 992.69 Mn 938.60 Mn
8 Biogen 31.89 Bn 30.60 Bn 1.96 Bn 24.78 Bn
9 Roivant Sciences 29.12 Bn 29.12 Bn 1.16 Mn 564.41 Mn
10 BioAtla 2.33 Mn 2.33 Mn - 5.25 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 5.25 Mn
Mar 31, 2026 5.47 Mn
Dec 31, 2025 5.82 Mn
Sep 30, 2025 6.24 Mn
Jun 30, 2025 6.52 Mn
Mar 31, 2025 753,000.00
Dec 31, 2024 1.19 Mn
Sep 30, 2024 1.67 Mn
Jun 30, 2024 2.15 Mn
Mar 31, 2024 2.77 Mn
Dec 31, 2023 3.25 Mn
Sep 30, 2023 3.85 Mn
Jun 30, 2023 4.33 Mn
Mar 31, 2023 4.84 Mn
Dec 31, 2022 5.31 Mn
Sep 30, 2022 5.80 Mn
Jun 30, 2022 6.30 Mn
Mar 31, 2022 6.63 Mn
Dec 31, 2021 7.13 Mn
Sep 30, 2021 4.06 Mn